Last updated: March 12, 2024
Sponsor: Lawson Health Research Institute
Overall Status: Active - Recruiting
Phase
N/A
Condition
Thrombocytopenia And Thrombocytopenia Prevention
Platelet Disorders
Treatment
Echocardiogram
neuro-cognitive assessment
CT Perfusion Study
Clinical Study ID
NCT03187652
108273
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Adults (=18 years) with a recent diagnosis of their first episode of idiopathic TTP,who have been treated with plasma exchange with or without other therapies, and whoare in remission. Remission is defined as the normalization of platelet counts andlactate dehydrogenase levels with no clinical signs or symptoms of microvascularinjury for more than 30 days. The patients will be included in the study within 30days of remission of their symptoms. The patients will all meet the followingdiagnostic criteria for idiopathic TTP: (1) thrombocytopenia with platelet count <150x 109 /L, (2) microangiopathic hemolytic anaemia (presence of red blood cellfragmentation by peripheral blood smear), (3) elevation of lactate dehydrogenase (LDH)> 1.25 X of the upper limit of normal, and (4) ADAMTS13 Activity < 10%
Exclusion
Exclusion Criteria:
- Patients will be excluded if they have diagnoses of typical HUS (diarrhea-associatedHUS), atypical HUS, and disseminated intravascular coagulation, have abnormalinternational normalized ratio at the time of presentation, have diagnoses ofmalignant hypertension at the time of presentation, are on the following drugs within 90 days prior to their presentation: ticlopidine, clopidogrel, mitomycin C,gemcitabine, cyclosporine, and quinine, have a history of hematopoietic stem celltransplantations prior to their presentation, have a history and/or diagnosis ofvasculitis, systemic lupus erythematosus, scleroderma, rheumatoid arthritis,antiphospholipid antibody syndrome, or HIV/AIDS, have a history of solid organmalignancy within 5 years prior to presentation, i.e. lung, breast, gastric, colon,pancreatic, prostate, or liver, are pregnant at the time of presentation, have severebronchospasm, unstable angina, and severe ischemic heart disease, have advanced kidneyfailure (estimated Glomerular Filtration Rate < 30 mL/min/1.73m2), and have history ofallergic reaction to contrast dye.
Study Design
Total Participants: 35
Treatment Group(s): 4
Primary Treatment: Echocardiogram
Phase:
Study Start date:
January 01, 2017
Estimated Completion Date:
January 01, 2026
Study Description
Connect with a study center
London Health Sciences Centre
London, Ontario N6A 5W9
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.